YS Biopharma Gets Phase I License for Hep B Vaccine
Ticker: LSBWF · Form: 6-K · Filed: Apr 18, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Ys Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, vaccine, hepatitis-b, biotech
TL;DR
YS Bio gets green light for Hep B vaccine Phase I trials.
AI Summary
YS Biopharma Co., Ltd. announced on April 18, 2024, that it has been granted a Phase I clinical trial license for its therapeutic chronic Hepatitis B Virus (HBV) vaccine. This license allows the company to proceed with early-stage human trials for its novel vaccine candidate.
Why It Matters
This development marks a significant step forward in the company's pipeline for treating chronic Hepatitis B, a major global health concern.
Risk Assessment
Risk Level: medium — Clinical trial success is inherently uncertain, and Phase I trials are just the first step in a long and expensive development process.
Key Players & Entities
- YS Biopharma Co., Ltd. (company) — Registrant
- Hepatitis B Virus (HBV) (medical_condition) — Target disease for vaccine
- Phase I (clinical_trial_phase) — Stage of clinical development
FAQ
What is the specific name of YS Biopharma's therapeutic chronic Hepatitis B Virus vaccine?
The filing does not specify the exact name of the vaccine, only that it is a therapeutic chronic Hepatitis B Virus vaccine.
When was the Phase I clinical trial license granted?
The press release, filed as an exhibit on April 18, 2024, announces the granting of the Phase I clinical trial license.
What is the primary goal of this Phase I clinical trial?
The goal is to conduct early-stage human trials for the therapeutic chronic Hepatitis B Virus vaccine.
What is YS Biopharma's former company name?
YS Biopharma Co., Ltd.'s former company name was YishengBio Co., Ltd.
Where is YS Biopharma's principal executive office located?
YS Biopharma's principal executive office is located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
Filing Stats: 178 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-04-18 08:15:21
Filing Documents
- ea0204148-6k_ysbio.htm (6-K) — 12KB
- ea020414801ex99-1_ysbio.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-033940.txt ( ) — 30KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission file number: 001-41687 YS BIOPHARMA CO., LTD. (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release – YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. YS Biopharma Co., Ltd. By: /s/ Hui Shao Name: Hui Shao Title: Director and Chief Executive Officer Date: April 18, 2024 2